Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
Gideon M. Hirschfield(University Health Network), Д. А. Шапиро(Cleveland Clinic), Cathi Sciacca(Intercept Pharmaceuticals (United States)), Velimir A. Luketic(University of Padua), O. Böhm(FGK Clinical Research), Henry C. Bodhenheimer(Mount Sinai Beth Israel), Stuart C. Gordon(United States Department of Veterans Affairs), Erin Castelloe(Intercept Pharmaceuticals (United States)), T. Beecher-Jones(Intercept Pharmaceuticals (United States)), Luciano Adorini(Intercept Pharmaceuticals (United States)), Keith D. Lindor(Mayo Clinic), Andrew L. Mason(Ochsner Medical Center), Hanns–Ulrich Marschall(University of Padua), Albert Parés(Corporació Sanitària Parc Taulí), Michael Trauner(Medical University of Vienna), Catherine Vincent(University of Padua), Kris V. Kowdley(Liver Institute Northwest), Marlyn J. Mayo(Southwestern Medical Center)
Cited by 563
Related Papers
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Simplified criteria for the diagnosis of autoimmune hepatitis†
|Hepatology|2008|1.9k